Gossamer Bio Secures $160M Partnership with Chiesi Group to Accelerate Development of Pulmonary Hypertension Treatment, $486M Potential for Seralutinib Collaboration
Portfolio Pulse from Benzinga Newsdesk
Gossamer Bio, Inc. (NASDAQ:GOSS) has entered into a $160M partnership with Chiesi Group to develop and commercialize seralutinib for pulmonary hypertension. This collaboration aims to accelerate seralutinib's development, particularly for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Gossamer will lead the development and US commercialization, sharing costs and profits with Chiesi, which will commercialize seralutinib outside the US. Gossamer could receive up to $486M in milestones.
May 06, 2024 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gossamer Bio's partnership with Chiesi Group for seralutinib's development could significantly impact its financials and market position in pulmonary hypertension treatment.
The partnership with Chiesi Group provides Gossamer Bio with substantial financial support and a strong collaboration to accelerate seralutinib's development and commercialization. The deal includes significant development reimbursement and potential for regulatory and sales milestones, which could enhance Gossamer's financial stability and growth prospects. The shared commitment to commercialization in the US and exclusive rights for Chiesi outside the US expands seralutinib's potential market reach, positively impacting GOSS's stock in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100